The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Kiniksa Pharmaceuticals, Ltd. (KNSA) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

Kiniksa Pharmaceuticals, Ltd. is one of 1003 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Kiniksa Pharmaceuticals, Ltd. is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for KNSA's full-year earnings has moved 182.9% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Our latest available data shows that KNSA has returned about 2.5% since the start of the calendar year. At the same time, Medical stocks have lost an average of 7%. This means that Kiniksa Pharmaceuticals, Ltd. is outperforming the sector as a whole this year.

Another stock in the Medical sector, Krystal Biotech, Inc. (KRYS), has outperformed the sector so far this year. The stock's year-to-date return is 6%.

For Krystal Biotech, Inc. the consensus EPS estimate for the current year has increased 19.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

Breaking things down more, Kiniksa Pharmaceuticals, Ltd. is a member of the Medical - Biomedical and Genetics industry, which includes 509 individual companies and currently sits at #85 in the Zacks Industry Rank. Stocks in this group have lost about 8.9% so far this year, so KNSA is performing better this group in terms of year-to-date returns. Krystal Biotech, Inc. is also part of the same industry.

Kiniksa Pharmaceuticals, Ltd. and Krystal Biotech, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Kiniksa Pharmaceuticals, Ltd. (KNSA) : Free Stock Analysis Report

Krystal Biotech, Inc. (KRYS) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research